Drug Trial Radar · NCT07492680
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
254
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Aug 15, 2028
Study completion May 20, 2032
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase 2 study evaluating Navlimetostat (BMS-986504) in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which Navlimetostat (BMS-986504) is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of Navlimetostat (BMS-986504) alone and in combination regimens.
Conditions
- Solid Tumors
Interventions
NavlimetostatDrug
Specified dose on specified days
DaraxonrasibDrug
Specified dose on specified days
TemozolomideDrug
Specified dose on specified days
PumitamigDrug
Specified dose on specified days
PemetrexedDrug
Specified dose on specified days
CarboplatinDrug
Specified dose on specified days
Nab-paclitaxelDrug
Specified dose on specified days
GemcitabineDrug
Specified dose on specified days
PaclitaxelDrug
Specified dose on specified days
CisplatinDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants who achieve Objective Response (OR)Time frame: Up to approximately 2 years
- Part 2: Number of participants with adverse events meeting protocol defined dose limiting toxicities (DLTs) criteriaTime frame: Up to approximately 2 years
- Part 2: Number of participants with adverse events (AE)Time frame: Up to approximately 2 years
- Part 2: Number of participants with Serious AEs (SAEs)Time frame: Up to approximately 2 years
- Part 2: Number of participants with treatment related AEsTime frame: Up to approximately 2 years
- Part 2: Number of participants with treatment related SAEsTime frame: Up to approximately 2 years
- Part 2: Number of participants with AEs leading to study treatment discontinuationTime frame: Up to approximately 2 years
- Part 2: Number of participants with AEs leading to deathTime frame: Up to approximately 2 years
- Part 2: Number of participants with laboratory abnormalitiesTime frame: Up to approximately 2 years
Locations
58 sites in 13 countries. Site status is shown where the registry gives one.
Local Institution - 0096
San Francisco, California · Not yet recruiting
Local Institution - 0182
Aurora, Colorado · Not yet recruiting
Emory University - Winship Cancer Institute
Atlanta, Georgia · Recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
Local Institution - 0124
Boston, Massachusetts · Not yet recruiting
Local Institution - 0119
Ann Arbor, Michigan · Not yet recruiting
Local Institution - 0129
Rochester, Minnesota · Not yet recruiting
Local Institution - 0174
Rochester, Minnesota · Not yet recruiting
Local Institution - 0181
Rochester, Minnesota · Not yet recruiting
Local Institution - 0142
Buffalo, New York · Not yet recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Local Institution - 0100
Durham, North Carolina · Not yet recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Local Institution - 0086
Seattle, Washington · Not yet recruiting
Local Institution - 0134
Madison, Wisconsin · Not yet recruiting
UZ Brussel
Brussels, Bruxelles-Capitale, Région de, Belgium · Recruiting
Cliniques universitaires Saint-Luc
Brussels, Bruxelles-Capitale, Région de, Belgium · Recruiting
UZ Gent
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Local Institution - 0051
Vancouver, British Columbia, Canada · Not yet recruiting
Local Institution - 0021
Toronto, Ontario, Canada · Not yet recruiting
Local Institution - 0007
Toronto, Ontario, Canada · Not yet recruiting
Local Institution - 0155
Beijing, Beijing Municipality, China · Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Local Institution - 0184
Guangzhou, Guangdong, China · Not yet recruiting
The First Affiliated Hospital of Henan Medical University
Xinxiang, Henan, China · Recruiting
Shanghai GoBroad Cancer Hospital China Pharmaceutical University
Shanghai, Shanghai Municipality, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Hôpital Saint-Louis
Paris, France · Recruiting
Centre Georges François Leclerc
Dijon, Côte-d'Or, France · Recruiting
Local Institution - 0075
Pierre-Bénite, Rhône, France · Not yet recruiting
Local Institution - 0116
Villejuif, Val-de-Marne, France · Not yet recruiting
Universitaetsklinikum Hamburg
Hamburg, Germany · Recruiting
Local Institution - 0039
Heidelberg, Germany · Not yet recruiting
Universitaetsklinikum Leipzig
Leipzig, Germany · Recruiting
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
Mainz, Germany · Recruiting
Klinikum Rechts der Isar der Technischen Universitaet Muenchen
München, Germany · Recruiting
Universitaetsklinikum Wuerzburg
Würzburg, Germany · Recruiting
Local Institution - 0150
Hksar, Hong Kong · Not yet recruiting
Local Institution - 0063
Shatin, Hong Kong · Not yet recruiting
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.